Sanofi inks deal with Melbourne-based manufacturing company

Pharma News: Sanofi has inked a deal with Melbourne-based pharmaceutical manufacturing company, focusing on manufacturing of messenger RNA (mRNA) vaccines.

Under this master service agreement, IDT Australia will collaborate closely with Sanofi to formulate and manufacture cGMP-compliant mRNA-based vaccines for clinical trials, targeting various medical needs currently unmet. The company also highlighted that it is one of the few aseptic sterile fill (injectables) facilities to complete mRNA downstream processing in Asia Pacific.

Paul McDonald, IDT Australia CEO, stated “We are thrilled to secure an agreement with Sanofi, progressing their groundbreaking science into cGMP manufacture to deliver mRNA product solutions to unmet medical needs.”

Sanofi’s Translational Science Hub (TSH) is a pioneering $280 million project with partners Griffith University, University of Queensland, and the Queensland Government. Leveraging the exceptional expertise and infrastructure in Queensland, this hub is designed to focus on mRNA vaccine technology and broader translational science.

“This collaboration with Sanofi underscores IDT Australia’s unique expertise and world-class facilities while reinforcing our position as a trusted partner in the global pharmaceutical industry,” added McDonald.

The imminent initial order, valued at approximately AUD $3 – $3.5 million, excludes expenses related to storage, shipping, and equipment procurement.

In a separate development, in January 2024, Sanofi acquired clinical-stage biopharmaceutical company, Inhibrx, for $1.7 billion. Specialising in oncology and orphan diseases, Inhibrx brings a robust pipeline of innovative biologic therapies to Sanofi’s portfolio.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.